ReviewCurrent medicinal chemistry2012
GCPII imaging and cancer.
Review in Current medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 78 citations in OpenAlex.
- Trial
- PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.Molecular imaging and biology · 2016Trial
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Trial
- Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2012Trial
- NAALADL1 modulates cellular resistance to Tumor Treating Fields in colorectal cancer.NPJ precision oncology · 2026Article
- Design, preclinical evaluation, and first-in-human PET study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Fully Automated Production of (((Pharmaceuticals (Basel, Switzerland) · 2025Article
- PSMA-Targeting Imprinted Nanogels for Prostate Tumor Localization and Imaging.Advanced healthcare materials · 2025Article
- Incidental discovery of gastrointestinal stromal tumor via PSMA-PET/CT imaging: Insights from a case report.Urology case reports · 2025Article
- Polymer-Tethered Quenched Fluorescent Probes for Enhanced Imaging of Tumor-Associated Proteases.ACS sensors · 2024Article
- Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen.Current oncology (Toronto, Ont.) · 2024Review
- Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled withACS pharmacology & translational science · 2024Article
- Polymer-tethered quenched fluorescent probes for enhanced imaging of tumor associated proteases.bioRxiv : the preprint server for biology · 2024Article
- PSMA-Targeted PET Radiotracer [Clinical and experimental gastroenterology · 2023Article
- Necessity of Pelvic Lymph Node Irradiation in Patients with Recurrent Prostate Cancer after Radical Prostatectomy in the PSMA PET/CT Era: A Narrative Review.Biomedicines · 2022Review
- [Scientific reports · 2022Article
- Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors.Biophysical reviews · 2022Review
- Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.Frontiers in medicine · 2022Review
- The Importance of Prostate-Specific Membrane Antigen Expression in Carotid Body Paragangliomas.Turkish archives of otorhinolaryngology · 2021Article
- Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer.Biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Glutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of imaging and therapy of prostate cancer using a wide variety of PSMA-targeting agents is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.